Vilon 20mg

Researchers evaluating Vilon should assess it as a research-use-only laboratory material, not a consumer product. Key considerations are compound identity, purity documentation, batch-specific COAs, lot traceability, product labeling, storage information, and supplier evaluation. This guide explains how qualified researchers can assess Vilon documentation, analytical testing, and RUO sourcing through Pure Lab Peptides.

Fast Answer: Reviewing Vilon for Laboratory Research

Researchers can buy Vilon online for laboratory research by reviewing RUO labeling, batch-specific COA documentation, purity data, identity information, storage guidance, and supplier transparency before selecting a source. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption.

Evaluating Research Procurement Documentation

Research-use-only sourcing should focus on objective documentation: label language, batch-specific certificate of analysis, lot number consistency, product form, compound identity, purity method, storage instructions, and supplier transparency. FDA guidance on RUO labeling is written for in vitro diagnostic products, but it illustrates the broader compliance principle that RUO labeling should align with the seller’s stated intended-use boundary and should not be contradicted by clinical or consumer positioning [1].

Vilon Research Material Overview

Vilon is commonly identified in chemical databases as lysylglutamic acid, Lys-Glu, or peptide vilon. PubChem lists lysylglutamic acid under CID 7010502 with molecular formula C11H21N3O5 and molecular weight 275.30 g/mol [2]. ChEBI-linked ontology records define Lys-Glu as a dipeptide formed from L-lysine and L-glutamic acid residues [3]. HMDB also lists related synonyms such as KE, L-Lys-L-Glu, lysyl-glutamate, and peptide vilon [4].

Vilon is a short peptide discussed in bioregulator research. That classification and the broader literature provide scientific context, not evidence of a supplier’s product performance or use guidance.

Vilon appears in research literature related to peptide identity, chromatin-associated cell models, gene-expression models, and short-peptide bioregulator discussions. A Biogerontology paper examined Vilon in cultured lymphocyte chromatin models [5]. Other publications have examined Lys-Glu in cell-culture or gene-expression settings, including splenocyte mRNA models and microarray-based models [6] [7]. These publications help define the research literature context for Vilon research material, but they do not establish instructions for RUO materials.

Before researchers buy Vilon, the evaluation should center on whether the supplier provides a clear research-use-only label, transparent product details, batch-specific COA access, a stated purity claim, analytical method information, and storage documentation. Vilon supplier documentation should also avoid therapeutic, diagnostic, veterinary, wellness, or personal-use framing.

Research Procurement Checklist for Vilon

• Verify that Vilon is labeled for research use only.
• Review the batch-specific certificate of analysis before procurement.
• Confirm that the COA includes identity and purity documentation.
• Check whether HPLC, LC-MS, mass spectrometry, or an equivalent analytical method is listed.
• Compare the product name, lot number, and documentation for consistency.
• Assess whether the supplier avoids therapeutic or human-use claims.
• Record storage and handling information in laboratory procurement files.
• Evaluate whether lyophilized powder form matches the research workflow.
• Confirm that the product is not marketed for human or animal consumption.

Vilon Quality Signals to Review Before Buying Online

Researchers comparing sources to buy Vilon online should prioritize documentation signals over promotional language. Analytical guidance documents describe identity, purity, assay, and impurity evaluation as distinct analytical concerns, and method validation frameworks emphasize that procedures should be fit for their intended analytical purpose [8] [9].

COA, Purity, and Identity Documentation

Vilon purity documentation should be read together with identity testing and lot traceability. A complete Vilon COA review should look for the compound name, lot number, test date, purity percentage, testing method, identity confirmation, molecular weight where relevant, sequence-related information where relevant, product form, and storage documentation.

A purity percentage alone does not establish complete compound identity; researchers should evaluate purity, identity, method, lot number, and documentation together. LC-MS workflows for synthetic peptides are used in impurity characterization, while FDA peptide guidance discusses peptide-related impurities in a drug-development context; these sources are useful for analytical background, not for making claims about RUO product use [13] [14].

Text version of this workflow

1. Receive the product and certificate of analysis (COA).
2. Is RUO labeling present? If no, flag the procurement gap. If yes, check the lot number.
3. Does the lot number match across the label and COA? If no, request batch-specific documentation. If yes, review analytical identity support.
4. Is identity supported by an analytical method? If no, request HPLC, LC-MS, or equivalent documentation. If yes, proceed.
5. Proceed to laboratory documentation and storage.

This workflow keeps Vilon identity testing, purity reporting, and lot matching in the same documentation review. It also separates procurement decisions from any interpretation of published literature.

Research Literature Context

Published literature has examined Vilon or Lys-Glu in several research settings, including cultured lymphocyte chromatin models, splenocyte gene-expression models, thymus-cell culture models, THP-1 monocyte/macrophage cell-line models, histone-complex interaction models, and short-peptide gene-expression reviews [15] [16] [17].

The evidence landscape is narrow and should be read cautiously. Some publications involve in vitro or cell-line models, some involve preclinical models, and some are reviews of short peptides rather than Vilon-specific procurement documentation. These sources provide scientific context, not verification of a supplier’s material. Published clinical literature does not establish suitability of RUO materials for non-research use.

Additional publications discuss short peptides in gene-expression or bioregulator frameworks, including plant callus expression models and broader reviews of peptide regulation of gene expression [18] [19] [20]. Researchers should distinguish those papers from Vilon supplier documentation, batch-specific COAs, and analytical test records.

Evidence Landscape

Vilon Product Form and Documentation at Pure Lab Peptides

Pure Lab Peptides presents Vilon 20mg as a research-use-only compound in lyophilized powder form with an ≥99% purity claim and batch-specific COA availability. Laboratory buyers should review the Pure Lab Peptides Vilon research-use-only product details for RUO labeling, product details, purity information, and batch-specific documentation.

The product documentation review should include the product page, Vilon purity documentation, Vilon identity testing information, storage and handling information, lot-level traceability, and Vilon supplier documentation. For broader sourcing context, researchers can also review the research peptide collection, the Pure Lab Peptides blogs, and shipping and returns information.

Common Misunderstandings About Buying Vilon Online

Misunderstanding 1: Vilon Is Intended for Personal Use

Vilon is supplied for laboratory research, not personal, consumer, wellness, therapeutic, diagnostic, or veterinary use. Researchers should evaluate supplier documentation, RUO labeling, COA availability, and lot traceability.

Misunderstanding 2: Published literature equals product-use guidance

Published Vilon literature provides scientific context, not instructions for RUO materials or verification of a supplier’s batch. Evaluate supplier claims against the documentation available for that batch.

Misunderstanding 3: Purity percentage alone proves identity

A high purity percentage is useful, but it is not complete identity documentation. Researchers should review the analytical method, compound name, lot number, molecular information, and identity confirmation. A Vilon COA should be evaluated as a full documentation package.

Misunderstanding 4: COA documentation does not need to be batch-specific

A COA is most useful when it is tied to a specific lot. Researchers should compare the lot number on the product label with the lot number on the COA. Batch-specific review supports traceability and helps prevent documentation mismatches.

Misunderstanding 5: RUO labeling supports human or animal consumption

RUO labeling does not support human or animal consumption. It limits the material to laboratory research.

Misunderstanding 6: Supplier claims can replace analytical documentation

Supplier descriptions cannot replace analytical documentation. Researchers should prioritize batch-specific COAs, identity testing, method information, storage documentation, lot traceability, and transparent RUO labeling when comparing Vilon sources.

FAQs About Buying Vilon Online for Research

Where can researchers buy Vilon online for laboratory research?

Researchers can buy Vilon online for laboratory research by selecting an RUO supplier that provides product labeling, batch-specific COA documentation, purity information, identity documentation, storage guidance, and lot-level traceability. Pure Lab Peptides provides a Vilon 20mg product page for researchers reviewing RUO product details and documentation.

What should researchers check before buying Vilon online?

Before buying Vilon online, researchers should check RUO labeling, the batch-specific COA, purity method, identity testing information, lot number consistency, product form, storage guidance, and supplier transparency. The review should remain procurement-focused and should not include operational or product-use assumptions.

Why does a COA matter when buying Vilon?

A COA matters when buying Vilon because it connects a specific lot to documented analytical results. Researchers should review the compound name, lot number, purity value, analytical method, identity information, test date, and product-form details. A COA is part of the procurement record, not a product-use instruction.

Is Vilon intended for human or animal consumption?

Vilon discussed in this article is not intended for human or animal consumption. The material is discussed only as a research-use-only compound for controlled laboratory settings. Researchers should avoid suppliers that frame Vilon as a consumer product or as material for therapeutic, diagnostic, veterinary, or wellness purposes.

What does research use only mean for Vilon?

Research use only for Vilon means the material is positioned for laboratory research and analytical evaluation, not clinical, diagnostic, veterinary, or personal use.

How should published literature about Vilon be interpreted?

Published literature about Vilon should be interpreted as scientific context. It may describe database identity, cell models, short-peptide frameworks, or analytical considerations, but it should not be converted into product-use guidance. Researchers should separate literature review from batch-specific procurement documentation.

Next Steps

For research teams comparing Vilon suppliers, prioritize COA availability, transparent RUO labeling, purity documentation, identity testing, storage information, and lot-level traceability. Review the Vilon 20mg product page for RUO labeling, purity information, product details, and available batch-specific documentation.

References

1. U.S. Food and Drug Administration. “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only.” FDA Guidance. 2013/2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only
2. National Center for Biotechnology Information. “PubChem Compound Summary for CID 7010502, Lysylglutamic acid.” PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lysylglutamic-acid
3. Gene Ontology Consortium and ChEBI. “Term Details for Lys-Glu, CHEBI:74557.” AmiGO 2. https://amigo.geneontology.org/amigo/term/CHEBI:74557
4. Human Metabolome Database. “Showing metabocard for Lysylglutamic acid, HMDB0028950.” HMDB. https://hmdb.ca/metabolites/HMDB0028950
5. Lezhava T, Khavison V, Monaselidze J, Jokhadze T, Dvalishvili N, Bablishvili N, Barbakadze S. “Bioregulator Vilon-Induced Reactivation of Chromatin in Cultured Lymphocytes from Old People.” Biogerontology. 2004. https://doi.org/10.1023/B:BGEN.0000025070.90330.7f
6. Kazakova TB, Barabanova SV, Khavinson VKh, Glushikhina MS, Parkhomenko EP, Malinin VV, Korneva EA. “In Vitro Effect of Short Peptides on Expression of Interleukin-2 Gene in Splenocytes.” Bulletin of Experimental Biology and Medicine. 2002. https://doi.org/10.1023/A:1020210615148
7. Anisimov SV, Bokheler KR, Khavinson VKh, Anisimov VN. “Studies of the Effects of Vilon and Epithalon on Gene Expression in Mouse Heart Using DNA-Microarray Technology.” Bulletin of Experimental Biology and Medicine. 2002. https://doi.org/10.1023/A:1015859322630
8. European Medicines Agency. “ICH Q2(R2) Validation of Analytical Procedures – Scientific Guideline.” EMA. 2023. https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline
9. U.S. Food and Drug Administration. “Analytical Procedures and Methods Validation for Drugs and Biologics.” FDA Guidance. 2015/2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics
10. International Organization for Standardization. “ISO/IEC 17025 – Testing and Calibration Laboratories.” ISO. 2017. https://www.iso.org/ISO-IEC-17025-testing-and-calibration-laboratories.html
11. Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet B, Hodges RS. “HPLC Analysis and Purification of Peptides.” Methods in Molecular Biology. 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC7119934/
12. Zeng K, Williams TD, Patel MK, et al. “Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Identification and Impurity Characterization.” Journal of Pharmaceutical and Biomedical Analysis. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4406950/
13. Lian Z, et al. “Characterization of Synthetic Peptide Therapeutics Using LC-MS.” Journal of the American Society for Mass Spectrometry. 2021. https://pubmed.ncbi.nlm.nih.gov/34110145/
14. U.S. Food and Drug Administration. “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin.” FDA Guidance for Industry. May 2021. FDA withdrawn-guidance record. Withdrawn July 28, 2026; cited for historical analytical context.
15. Sevostianova NN, Linkova NS, Polyakova VO, Chervyakova NA, Kostylev AV, Durnova AO, Kvetnoy IM, Abdulragimov RI, Khavinson VH. “Immunomodulating Effects of Vilon and Its Analogue in the Culture of Human and Animal Thymus Cells.” Bulletin of Experimental Biology and Medicine. 2013. https://doi.org/10.1007/s10517-013-2000-0
16. Avolio F, Martinotti S, Khavinson V, et al. “Peptides Regulating Proliferative Activity and Inflammatory Pathways in Human Monocytic THP-1 Cell Line.” International Journal of Molecular Sciences. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/
17. Fedoreyeva LI, Smirnova TA, Kolomijtseva GY, Khavinson VKh, Vanyushin BF. “Interaction of Short Peptides with FITC-Labeled Wheat Histones and Their Complexes with Deoxyribooligonucleotides.” Biochemistry Moscow. 2013. https://pubmed.ncbi.nlm.nih.gov/23581987/
18. Fedoreyeva LI, Dilovarova TA, Ashapkin VV, Martirosyan YT, Khavinson VK, Kharchenko PN, Vanyushin BF. “Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum.” Biochemistry Moscow. 2017. https://doi.org/10.1134/S0006297917040149
19. Khavinson VK, Linkova NS, Tarnovskaya SI, et al. “Peptide Regulation of Gene Expression: A Systematic Review.” Molecules. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8619776/
20. Khavinson VK, et al. “Short Peptides Regulate Gene Expression.” Bulletin of Experimental Biology and Medicine. 2016. https://pubmed.ncbi.nlm.nih.gov/27909961/
21. Fosgerau K, Hoffmann T. “Peptide Therapeutics: Current Status and Future Directions.” Drug Discovery Today. 2015. https://pubmed.ncbi.nlm.nih.gov/25450771/
22. Khavinson VK, Kvetnoii IM. “Peptide Bioregulators Inhibit Apoptosis.” Bulletin of Experimental Biology and Medicine. 2000. https://doi.org/10.1007/BF02682019